• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4595849)   Today's Articles (2461)   Subscriber (49335)
Number Citation Analysis
26
Zhang H, Jiang J, He X, Zhou Q. Circ_0002111/miR-134-5p/FSTL1 signal axis regulates tumor progression and glycolytic metabolism in papillary thyroid carcinoma cells. J Endocrinol Invest 2023;46:713-725. [PMID: 36227499 DOI: 10.1007/s40618-022-01921-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 09/11/2022] [Indexed: 10/17/2022]
27
Gu Y, Xu W, Liu Y, An X, Li J, Cong L, Zhu L, He X, Wang H, Jiang Y. The feasibility of a novel computer-aided classification system for the characterisation and diagnosis of breast masses on ultrasound: a single-centre preliminary test study. Clin Radiol 2023:S0009-9260(23)00130-7. [PMID: 37069025 DOI: 10.1016/j.crad.2023.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Revised: 03/07/2023] [Accepted: 03/15/2023] [Indexed: 04/19/2023]
28
Garassino M, Kilickap S, Özgüroğlu M, Sezer A, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Fuang H, Kulyaba Y, Dvorkin M, Zyuhal K, Scheusan RI, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
29
Yu SY, He X, Tian ZL, Li KX, Chen H, Wang HM, Shi ZS, Zhu S, Cui ZC. Effect of Collagen-Reactive Functional Monomer on Etch-and-Rinse Adhesives. J Dent Res 2023;102:287-294. [PMID: 36474440 DOI: 10.1177/00220345221134278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]  Open
30
Zhao J, Ip DKM, Leung JYY, Vackova D, He X, Schooling CM. Effect of berberine on cardiovascular disease risk factors: abridged secondary publication. Hong Kong Med J 2023;29 Suppl 2:39-41. [PMID: 36951006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/24/2023]  Open
31
Wang B, Deng Y, Xu Q, Gao J, Shen H, He X, Ding Q, Wang F, Guo H. Exploration of 68Ga-labelled prostate-specific membrane antigen-11 PET/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma. Clin Radiol 2023;78:e417-e424. [PMID: 36805287 DOI: 10.1016/j.crad.2023.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 12/26/2022] [Accepted: 01/10/2023] [Indexed: 02/04/2023]
32
Sun H, Song J, Li K, Li Y, Shang L, Zhou Q, Lu Y, Zong Y, He X, Kari M, Yang H, Zhou X, Zhang L, Tang B. Increased β1-adrenergic receptor antibody confers a vulnerable substrate for atrial fibrillation via mediating Ca2+ mishandling and atrial fibrosis in active immunization rabbit models. Clin Sci (Lond) 2023;137:195-217. [PMID: 36597894 PMCID: PMC9885845 DOI: 10.1042/cs20220654] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Revised: 12/19/2022] [Accepted: 01/03/2023] [Indexed: 01/05/2023]
33
Chen M, Chen YM, Lu Y, He X, Peng H, Zhang HY. [Cryptic COL1A1-PDGFB fusion in dermatofibrosarcoma protuberans: a clinicopathological and genetic analysis]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2023;52:13-18. [PMID: 36617900 DOI: 10.3760/cma.j.cn112151-20221006-00832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
34
He X, Zheng Y, Wang J. Neoadjuvant Chemotherapy Efficacy and Safety in Borderline Resectable Pancreatic Cancer. Indian J Pharm Sci 2023. [DOI: 10.36468/pharmaceutical-sciences.spl.613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]  Open
35
L. Zuo, Zhou S, Liu P, Yang S, Yang J, He X, Gui L, Li R, Yang Y. 106P Zanubrutinib in combination with tislelizumab in patients with refractory diffuse large B cell lymphoma (DLBCL): A phase II study. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
36
Zhou S, Zuo L, Yang S, He X, Yang J, Gui L, Li R, Yang Y. 99P Sintilimab plus nab-paclitaxel in platinum-refractory head and neck squamous cell carcinoma: A phase II trial. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
37
Ho G, Sezer A, Kilickap S, Gumus M, Bondarenko I, Ozguroglu M, Gogishvili M, He X, Gullo G, Rietschel P, Quek R. 334P Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]  Open
38
Zheng X, Zhang L, Liu X, Qu B, Zhong Q, Qian L, Yang Y, Xiaorong H, Qiao X, Wang H, Zhu Y, Cao J, Wu J, Wu T, Zhu S, Shi M, Zhang H, Zhang X, Su H, Song Y, Zhu J, Zhang Y, Huang H, Wang Y, Chen F, Yin L, He X, He X, Qi S, Li Y. Pattern and Prognosis of Distant Metastases in Patients with Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
39
Gui L, He X, Yang J, Liu P, Qin Y, Shi YK. 230MO Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]  Open
40
Xin L, Zhang L, Qu B, Zhong Q, Qian L, Yang Y, Xiaorong H, Qiao X, Wang H, Zhu Y, Wu J, Wu T, Zhu S, Shi M, Zhang H, Zhang X, Su H, Song Y, Zhu J, Zhang Y, Huang H, Wang Y, Chen F, Yin L, He X, Cai S, Qi S, Li Y. Evidence of Cure for Extranodal Nasal-Type NK/T-Cell Lymphoma with Modern Treatment. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
41
Gui L, He X, Yang J, Liu P, Yan Q, Shi YK. 683P Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
42
Kilickap S, Sezer A, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, He X, Gullo G, Rietschel P, Quek R. P1.15-12 Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
43
Lin Y, Yang H, Shi F, Yang A, Han X, Liu B, Li Z, Ji Q, Tang L, Deng Z, Ding Y, Fu W, Xie X, Li L, He X, Lv Z, Wu L, Liu L. 1644O Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1724] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]  Open
44
Xiao W, Chen L, Xuan T, He X, Yu H, Zhu X, Luo N, Li M, Qi Y, Sun T, Qi C. 1769P KDM6A mutation act as a potential immunotherapy biomarker in urothelial carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
45
Kalinka-Warzocha E, Gogishvili M, Makharadze T, Dvorkin M, Penkov K, Laktionov K, Nechaeva M, Rozhkova I, He X, Quek R, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. 954P Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]  Open
46
Yan Z, Wan X, Li Y, Zhao K, Huang Y, He X, Zhang X, Ma X, Liu Y, Niu H, Shu K, Zhang H, Lei T. Safety and efficacy of extra-ventricular drainage combined with urokinase administration in the management of intraventricular hemorrhage. Neurochirurgie 2022;68:e53-e59. [DOI: 10.1016/j.neuchi.2022.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 06/29/2022] [Accepted: 07/05/2022] [Indexed: 11/26/2022]
47
He X, Wang Y, Zhao S, Chen X. 302 A novel end-to-end deep learning framework for skin lesion segmentation and classification in clinical images. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
48
Sun Z, Qiu YY, He X, Liu L. [Investigation of the occurrence of musculoskeletal disorders at shoulder, neck and elbow of digestive endoscopy operators]. ZHONGHUA LAO DONG WEI SHENG ZHI YE BING ZA ZHI = ZHONGHUA LAODONG WEISHENG ZHIYEBING ZAZHI = CHINESE JOURNAL OF INDUSTRIAL HYGIENE AND OCCUPATIONAL DISEASES 2022;40:430-434. [PMID: 35785896 DOI: 10.3760/cma.j.cn121094-20210119-00037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
49
KELLNEROVÁ S, Stampfer K, Skjødt M, Rosbjerg A, Bayarri-Olmos R, Talasz H, He X, Garred P, Orth-Höller D, Grasse M, Würzner R. POS-002 CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINST DIFFERENT FORMS OF THE A SUBUNIT OF SHIGA TOXIN 2a. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.04.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]  Open
50
Papadimitriou TI, van Caam A, Lemmers J, He X, Vitters E, Koenders M, Smeets R, Vonk M, van der Kraan P, Koenen H, Thurlings RM. AB0139 DEEP IMMUNE PHENOTYPING OF T LYMPHOCYTE SUBSETS IN SYSTEMIC SCLEROSIS PATHOPHYSIOLOGY AND FOLLOWING RESPONSE TO TARGETED CYTOTOXIC TREATMENT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
PrevPage 2 of 42 123454142Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA